<DOC>
	<DOCNO>NCT01856127</DOCNO>
	<brief_summary>This three-center , randomize , double-blind , fix dose study design assess efficacy , safety , tolerability switch vilazodone sexual dysfunction associate use selective serotonin reuptake inhibitor ( SSRI ) serotonin-norepinephrine reuptake inhibitor ( SNRI ) compare switch sertraline patient Major Depressive Disorder ( MDD ) . Vilazodone newly introduce , FDA approve antidepressant combine serotonin specific reuptake inhibitor serotonin 1A receptor partial agonist . In contrast SSRIs SNRIs , appear low adverse effect sexual functioning compare placebo .</brief_summary>
	<brief_title>Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction ?</brief_title>
	<detailed_description>The design randomize , double blind study patient randomize switch either vilazodone sertraline . This consist 1-week Screening phase , 2-week Cross Taper phase , 8-week Treatment phase , optional 2-week Down taper phase . The total duration patient 's participation 13 week . Seventy-two patient randomize Baseline visit either vilazodone sertraline , 24 3 site . Patients recruit 12 month .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>1 . Patients must able understand nature study , agree comply prescribed dosage regimen , report regularly schedule office visit , communicate study personnel adverse event concomitant medication use ; 2 . Patients major depressive disorder treat selective serotonin reuptake inhibitor ( citalopram , escitalopram , fluvoxamine , paroxetine ) serotoninnorepinephrine reuptake inhibitor ( desvenlafaxine , duloxetine , venlafaxine ) minimum 8 week . 3 . The current episode MDD remission ( MADRS score &lt; 10 CGI score 1 2 ) 4 . The duration current MDD episode le 2 year 5 . Presence antidepressantassociated sexual dysfunction ( i.e. , absence sexual dysfunction prior become depress presence significant dysfunction SSRI SNRI despite remission depression ) . 6 . Patient least 18 year old 65 year old 7 . Patients must opportunity sexual activity study period ( form availability suitable partner sexual activity and/or openness masturbation ) 8 . Patients must willing attempt sexual activity ( include masturbation ) least every two week study 1 . Patients previously fail respond tolerate either vilazodone sertraline . 2 . Patients history severe discontinuation symptom taper current antidepressant 3 . Patients know cause sexual dysfunction 4 . Use prohibit medication study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sexual Dysfunction</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Major Depressant</keyword>
	<keyword>SSRI</keyword>
	<keyword>SNRI</keyword>
	<keyword>Vilazodone</keyword>
	<keyword>Sertraline</keyword>
</DOC>